T5	eligibility 132 162	women with early breast cancer
T7	control 757 775	standard treatment
T8	eligibility 403 461	women with early, hormone-receptor positive, breast cancer
T9	outcome-Measure 1189 1237	evolution of scores for joint pain and stiffness
T10	outcome-Measure 1243 1292	impact of pain on sleep and analgesic consumption
T11	total-participants 1340 1345	Forty
T12	age 1365 1379	64.9±8.1 years
T13	intervention-participants 1397 1399	20
T16	outcome 1657 1696	individual components of the pain score
T15	outcome 1529 1567	evolution of mean composite pain score
T18	cv-bin-abs 1789 1793	Nine
T19	cv-bin-percent 1815 1818	45%
T20	iv-bin-abs 1824 1825	1
T21	iv-bin-percent 1827 1829	5%
T22	outcome 1939 1977	joint pain had a worse impact on sleep
T23	cv-bin-percent 2002 2005	35%
T24	iv-bin-percent 2010 2012	0%
T14	iv-cont-mean 1605 1609	-1.3
T26	cv-cont-mean 1625 1629	+3.4
T1	intervention 15 61	Ruta graveolens 5CH and Rhus toxicodendron 9CH
T2	condition 73 97	joint pain and stiffness
T4	iv-cont-mean 2294 2298	37.7
T6	iv-cont-sd 2299 2303	23.0
T17	cv-cont-mean 2308 2312	17.9
T27	cv-cont-sd 2313 2321	20.1 min
T25	outcome 2069 2111	evolution of morning and daytime stiffness
T3	outcome 1858 1879	analgesic consumption
